glp-1 obesity drug news updates The next phase of the race What is the pipeline for
Description
Why the first non-peptide oral GLP-1 is drawing serious attentionand where caution still applies
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.
Gastrointestinal (GI) adverse eventsparticularly nausea, vomiting, diarrhea, and constipationare the most common side effects, generally emerging during dose escalation and resolving over time
Call us today.
Explore the pros and cons of GLP-1 medications for managing type 2 diabetes and weight loss.
